MNCFO - Survey on Empirical antibiotic SelectionMCI Registration NumberFULL NAME (As in your Pancard)EmailPhone/MobileCityStateSpecialityBank DetailsAccount Holder NameA/c NumberIFSC CodeUpload Cancelled Cheque (Max Size - 2 MB)Choose File Pancard NumberUpload Pancard Details (Max Size - 2 MB)Choose File SURVEY ON EMPIRICAL ANTIBIOTIC SELECTION FOR COMMUNITY-ACQUIRED LRTIS IN INDIAN SETTINGS MCQ Questionnaire1. What proportion of adult outpatient visits presenting with lower respiratory tract symptoms (cough with purulent sputum, fever, dyspnea) do you diagnose as bacterial LRTIs in your routine practice? Less than 20% 20% – 40% 41% – 60% More than 60%2. Which clinical presentation is the primary trigger for you to initiate empirical oral antibiotic therapy in suspected community-acquired LRTIs? Persistent purulent/mucopurulent sputum with high-grade fever (More than 3 days) Anthonisen Type 1 criteria in COPD patients (increased dyspnea, sputum volume, and purulence) Elevated inflammatory markers (e.g., CRP / high ESR / leukocytosis) Auscultatory findings of localized crackles/crepitations and rhonchi3. Which class of oral antimicrobials is your most frequent first-line empirical choice for uncomplicated, non-hospitalized community-acquired LRTIs? Oral 3rd Generation Cephalosporins (e.g., Cefpodoxime, Cefixime) Beta-lactam + Beta-lactamase inhibitor combinations (e.g., Amoxicillin-Clavulanate) Macrolides / Azalides (e.g., Azithromycin, Clarithromycin) Respiratory Fluoroquinolones (e.g., Levofloxacin, Moxifloxacin)4. What is your primary clinical rationale when choosing Cefpodoxime over Amoxicillin-Clavulanate for empirical management of LRTIs? Significantly lower incidence of antibiotic-associated diarrhea and GI intolerance Superior pharmacokinetic/pharmacodynamic (PK/PD) profile against penicillin-resistant Streptococcus pneumoniae Better patient compliance due to twice-daily dosing and smaller tablet size High stability against beta-lactamase producing organisms without clavulanate-mediated hepatic stress5. When evaluating oral 3rd generation cephalosporins for respiratory tract coverage, how do you rank Cefpodoxime versus Cefixime? Cefpodoxime is preferred due to superior intrinsic Gram-positive coverage (Streptococcus pneumoniae, Staphylococcus aureus) Ceffixime is preferred due to broader Gram-negative coverage Both are therapeutically equivalent in respiratory tract infections Cefpodoxime is preferred primarily for switch therapy following IV Ceftriaxone/Cefotaxime6. What is your standard dosing protocol for Cefpodoxime Proxetil in adult patients with moderate Acute Bronchitis or mild-to-moderate CAP? 100 mg twice daily (BD) for 5 days 200 mg twice daily (BD) for 5 to 7 days 200 mg twice daily (BD) for 10 to 14 days 400 mg once daily (OD) for 7 days7. In which specific clinical subset do you find Cefpodoxime most effective as empirical monotherapy? Acute exacerbations of chronic bronchitis / mild AECOPD without risk factors for Pseudomonas Outpatient mild CAP in elderly patients with comorbidities (e.g., Diabetes, Hypertension) Secondary bacterial infections following viral respiratory infections (post-influenza/post-viral bronchitis) Step-down therapy following initial clinical stabilization with parenteral cephalosporins8. How frequently do you co-prescribe an oral Macrolide (e.g., Azithromycin) alongside Cefpodoxime for suspected atypical pathogens (Mycoplasma, Chlamydia) in CAP? Routinely (More than 60% of cases) Selectively in younger adults or during seasonal atypical outbreaks (20% – 50% of cases) Rarely (Less than 20% of cases), preferring monotherapy to prevent resistance Never; switch to monotherapy with a Respiratory Fluoroquinolone instead9. What is the primary clinical safety and tolerability advantage of Cefpodoxime Proxetil compared to aminopenicillin-clavulanate regimens in LRTI patients? Markedly lower incidence of secretory diarrhea and dysbiosis Reduced risk of drug-induced gastric mucosal irritation and nausea Negligible risk of cholestatic jaundice / clavulanate-associated hepatotoxicity Superior safety profile in patients with mild renal function impairment10. What is your major concern when prescribing empirical oral antibiotics for outpatient respiratory infections in your geographic region? Escalating rates of cephalosporin and macrolide resistance in common respiratory pathogens Patient non-compliance and early discontinuation once fever subsides Over-the-counter dispensing and prior self-medication by patients Differentiating viral vs. bacterial etiology in the absence of rapid point-of-care diagnostics I have read and agree to the Terms and Conditions .Submit Form